公开(公告)号：EP2828247A1

公开(公告)日：2015-01-28

申请号：EP13763520.7

申请日：2013-03-14

申请人： PTC Therapeutics, Inc.

发明人： YANG, Tianle ,  KARP, Gary, Mitchell ,  QI, Hongyan

IPC分类号： C07D311/00 ,  A01N43/16 ,  A61K31/35

CPC分类号： C07D405/04 ,  A61K31/352 ,  C07D311/22 ,  C07D311/26 ,  C07D311/30 ,  C07D405/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

摘要： Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

公开(公告)号：EP2435437A1

公开(公告)日：2012-04-04

申请号：EP10781168.9

申请日：2010-05-27

申请人： PTC Therapeutics, Inc.

发明人： HWANG, Peter, Seongwoo ,  MOON, Young-choon ,  ARASU, Tamil ,  QI, Hongyan ,  ALMSTEAD, Neil

IPC分类号： C07D471/04 ,  A61K31/44

CPC分类号： C07D471/04

摘要： Provided herein are improved processes for the synthesis of substituted tetrahydro beta-carboline derivatives. In particular, provided herein are improved processes useful for the preparation of (S)-4-chlorophenyl 6-chloro- 1 -(4-methoxyphenyl)-3,4-dihydro- 1 H-pyrido [3,4-b]indole-2(9H)-carboxylate. Formula (I)

公开(公告)号：EP1824821A2

公开(公告)日：2007-08-29

申请号：EP05852076.8

申请日：2005-11-23

申请人： PTC Therapeutics, Inc.

发明人： CAO, Liangxian ,  CHOI, Soongyu ,  MOON, Young-choon ,  TAMILARASU, Nadarajan ,  QI, Hongyan ,  LENNOX, William Joseph ,  HWANG, Seongwoo

IPC分类号： C07D209/88 ,  C07D495/04 ,  C07D317/66 ,  C07D209/94 ,  C07D261/14 ,  C07D213/82 ,  C07D498/22 ,  C07D271/10 ,  C07D285/06 ,  C07D487/22 ,  C07D307/84 ,  C07D307/68 ,  C07D333/38 ,  C07D263/32 ,  C07D239/42

CPC分类号： A61K31/403 ,  A61K31/343 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/424 ,  A61K31/4245 ,  A61K31/506 ,  A61K31/5377 ,  C07D209/08 ,  C07D209/90 ,  C07D471/04

摘要： In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds and compositions useful in the inhibition of BEGF production, and/or in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.